Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide for GVHD prophylaxis in higher-risk MDS, CMML, and secondary AML
KCT0004151Phase 2Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Asan Medical Center. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0004151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004151.